Liver function may predict dangerous side effect in common breast cancer drug
NCT ID NCT05912933
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study looks at whether breast cancer patients with mild, moderate, or severe liver problems face a higher risk of a serious side effect—grade 4 neutropenia (a dangerous drop in infection-fighting white blood cells)—when taking the drug palbociclib. Researchers analyzed medical records from over 1,300 patients across 23 hospitals in Japan. The goal is to understand how liver impairment influences this side effect, which could help doctors tailor treatment and monitoring for these patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
palbociclib
What this could lead to
If it works, this could help doctors better predict and manage severe neutropenia risk in breast cancer patients with liver problems who take palbociclib.
What could go wrong
This is an observational study using existing data, not a controlled trial. Results may not apply to all populations or settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer New York
New York, New York, 10001, United States